Mamelle N, Meunier P J, Dusan R, Guillaume M, Martin J L, Gaucher A, Prost A, Zeigler G, Netter P
INSERM Unit 265, Lyon, France.
Lancet. 1988 Aug 13;2(8607):361-5. doi: 10.1016/s0140-6736(88)92834-6.
The risk-benefit ratio of combined fluoride-calcium therapy in primary vertebral osteoporosis was examined prospectively in patients with at least one vertebral fracture. 257 patients were randomised to receive sodium fluoride 25 mg twice daily plus elemental calcium 1 g daily and a vitamin D2 supplement, and 209 received one of the alternative therapies usually prescribed in France. After a follow-up of 24 months the fluoride-calcium group showed a significantly lower rate of new vertebral fractures, the main adverse effect of the regimen being a higher incidence of osteoarticular pains in the ankle and foot; the risk of non-vertebral fractures was not increased, and digestive disorders arose with equal frequency in the two groups. Sodium fluoride 50 mg daily seems to represent a reasonable compromise in terms of anti-fracture effectiveness and side-effects.
对至少有一处椎体骨折的原发性椎体骨质疏松症患者，前瞻性地研究了联合使用氟化物 - 钙疗法的风险效益比。257例患者被随机分组，接受每日两次25毫克氟化钠加每日1克元素钙及维生素D2补充剂，209例患者接受法国通常开具的替代疗法之一。随访24个月后，氟化物 - 钙组的新椎体骨折发生率显著降低，该治疗方案的主要不良反应是踝关节和足部骨关节炎疼痛的发生率较高；非椎体骨折的风险未增加，两组出现消化系统疾病的频率相同。就抗骨折效果和副作用而言，每日50毫克氟化钠似乎是一个合理的折衷方案。
